Potentiality of Protein Phosphatase Mg /Mn Dependent 1D As a Biomarker for Predicting Prognosis in Acute Myeloid Leukemia Patients

Overview

Journal J Clin Lab Anal

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
Pathology

Date 2020 Jan 5

PMID 31901183

Citations 3

Authors

Meijia Yu

Jie Hu

Di He

Qi Chen

Suna Liu

Xiaoling Zhu

Bin Li

Affiliations

Soon will be listed here.

Abstract

Objective: The present study aimed to investigate the correlation of protein phosphatase Mg /Mn dependent 1D (PPM1D) with the risk stratification, treatment response, and survival profile in acute myeloid leukemia (AML) patients.

Methods: Totally 221 de novo AML patients and 50 healthy donors were enrolled. The bone marrow samples were collected before treatment from AML patients and acquired after enrollment from healthy donors. And bone marrow mononuclear cells were separated for detecting the mRNA/protein expressions of PPM1D by reverse transcription-quantitative polymerase chain reaction and Western blot. Complete remission (CR) was assessed after induction treatment, and event-free survival (EFS) and overall survival (OS) were calculated in AML patients.

Results: PPM1D mRNA (P < .001)/protein (P < .001) relative expressions were increased in AML patients compared with healthy donors, and receiver operating characteristic curve presented that PPM1D mRNA (AUC: 0.728, 95% CI: 0.651-0.806)/protein (AUC: 0.782, 95% CI: 0.707-0.857) relative expressions could differentiate AML patients from healthy donors. In AML patients, PPM1D mRNA (P < .001)/protein (P < .001) high relative expressions were correlated with poor-risk stratification. As for its association with prognosis, PPM1D mRNA (P < .001)/protein (P = .010) relative expressions were elevated in CR patients compared with non-CR patients. Patients with PPM1D mRNA (P < .001 for EFS; P = .004 for OS)/protein (P < .001 for EFS; P = .006 for OS) high relative expressions exhibited reduced EFS and OS compared with those with low expressions.

Conclusion: PPM1D high expression correlates with poor-risk stratification and might serve as a potential biomarker for worse prognosis in AML patients, suggesting its potential to guide AML management.

Citing Articles

Identification of two key biomarkers CD93 and FGL2 associated with survival of acute myeloid leukaemia by weighted gene co-expression network analysis.

Han H, Liu J, Zhu S, Zhao T J Cell Mol Med. 2024; 28(14):e18552.

PMID: 39054581 PMC: 11272607. DOI: 10.1111/jcmm.18552.

Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a.

Fontana M, Nanni J, Luserna di Rora A, Petracci E, Padella A, Ghetti M Biomedicines. 2021; 9(4).

PMID: 33917342 PMC: 8067413. DOI: 10.3390/biomedicines9040388.

Potentiality of Protein phosphatase Mg /Mn dependent 1D as a biomarker for predicting prognosis in acute myeloid leukemia patients.

Yu M, Hu J, He D, Chen Q, Liu S, Zhu X J Clin Lab Anal. 2020; 34(5):e23171.

PMID: 31901183 PMC: 7246369. DOI: 10.1002/jcla.23171.

References

Piemontese S, Ciceri F, Labopin M, Bacigalupo A, Huang H, Santarone S . A survey on unmanipulated haploidentical hematopoietic stem cell transplantation in adults with acute leukemia. Leukemia. 2014; 29(5):1069-75. DOI: 10.1038/leu.2014.336. View

Yang S, Dong S, Qu X, Zhong X, Zhang Q . Clinical significance of Wip1 overexpression and its association with the p38MAPK/p53/p16 pathway in NSCLC. Mol Med Rep. 2016; 15(2):719-723. PMC: 5364870. DOI: 10.3892/mmr.2016.6032. View

Kadam P, Chuan H . Erratum to: Rectocutaneous fistula with transmigration of the suture: a rare delayed complication of vault fixation with the sacrospinous ligament. Int Urogynecol J. 2016; 27(3):505. DOI: 10.1007/s00192-016-2952-5. View

Yoda A, Toyoshima K, Watanabe Y, Onishi N, Hazaka Y, Tsukuda Y . Arsenic trioxide augments Chk2/p53-mediated apoptosis by inhibiting oncogenic Wip1 phosphatase. J Biol Chem. 2008; 283(27):18969-79. DOI: 10.1074/jbc.M800560200. View

Kong W, Jiang X, Mercer W . Downregulation of Wip-1 phosphatase expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-mediated transcriptional activation of Bax. Cancer Biol Ther. 2009; 8(6):555-63. DOI: 10.4161/cbt.8.6.7742. View

Kamada R, Kudoh F, Yoshimura F, Tanino K, Sakaguchi K . Inhibition of Ser/Thr phosphatase PPM1D induces neutrophil differentiation in HL-60 cells. J Biochem. 2017; 162(4):303-308. DOI: 10.1093/jb/mvx032. View

Li Z, Zhang L, Gao X, Jiang X, Sun L . Expression and significance of the Wip1 proto-oncogene in colorectal cancer. Asian Pac J Cancer Prev. 2013; 14(3):1975-9. DOI: 10.7314/apjcp.2013.14.3.1975. View

Hsu J, Dayaram T, Tovy A, De Braekeleer E, Jeong M, Wang F . PPM1D Mutations Drive Clonal Hematopoiesis in Response to Cytotoxic Chemotherapy. Cell Stem Cell. 2018; 23(5):700-713.e6. PMC: 6224657. DOI: 10.1016/j.stem.2018.10.004. View

Yu M, Hu J, He D, Chen Q, Liu S, Zhu X . Potentiality of Protein phosphatase Mg /Mn dependent 1D as a biomarker for predicting prognosis in acute myeloid leukemia patients. J Clin Lab Anal. 2020; 34(5):e23171. PMC: 7246369. DOI: 10.1002/jcla.23171. View

10.

Wang P, Ye J, Hou C, Zhou D, Zhan S . Combination of lentivirus-mediated silencing of PPM1D and temozolomide chemotherapy eradicates malignant glioma through cell apoptosis and cell cycle arrest. Oncol Rep. 2016; 36(5):2544-2552. PMC: 5055212. DOI: 10.3892/or.2016.5089. View

11.

Wu B, Guo B, Kang J, Deng X, Fan Y, Zhang X . PPM1D exerts its oncogenic properties in human pancreatic cancer through multiple mechanisms. Apoptosis. 2015; 21(3):365-78. DOI: 10.1007/s10495-015-1211-4. View

12.

Dohner H, Estey E, Amadori S, Appelbaum F, Buchner T, Burnett A . Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2009; 115(3):453-74. DOI: 10.1182/blood-2009-07-235358. View

13.

Tallman M, Wang E, Altman J, Appelbaum F, Bhatt V, Bixby D . Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019; 17(6):721-749. DOI: 10.6004/jnccn.2019.0028. View

14.

Xu Z, Cao C, Xia H, Shi S, Hong L, Wei X . Protein phosphatase magnesium-dependent 1δ is a novel tumor marker and target in hepatocellular carcinoma. Front Med. 2016; 10(1):52-60. DOI: 10.1007/s11684-016-0433-3. View

15.

Ramos N, Mo C, Karp J, Hourigan C . Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. J Clin Med. 2015; 4(4):665-95. PMC: 4412468. DOI: 10.3390/jcm4040665. View

16.

Fiscella M, Zhang H, Fan S, Sakaguchi K, Shen S, Mercer W . Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. Proc Natl Acad Sci U S A. 1997; 94(12):6048-53. PMC: 20998. DOI: 10.1073/pnas.94.12.6048. View

17.

Ali A, Abedini M, Tsang B . The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Oncogene. 2011; 31(17):2175-86. DOI: 10.1038/onc.2011.399. View

18.

Zane L, Yasunaga J, Mitagami Y, Yedavalli V, Tang S, Chen C . Wip1 and p53 contribute to HTLV-1 Tax-induced tumorigenesis. Retrovirology. 2012; 9:114. PMC: 3532233. DOI: 10.1186/1742-4690-9-114. View

19.

Oghabi Bakhshaiesh T, Majidzadeh-A K, Esmaeili R . Wip1: A candidate phosphatase for cancer diagnosis and treatment. DNA Repair (Amst). 2017; 54:63-66. DOI: 10.1016/j.dnarep.2017.03.004. View

20.

Dohner H, Weisdorf D, Bloomfield C . Acute Myeloid Leukemia. N Engl J Med. 2015; 373(12):1136-52. DOI: 10.1056/NEJMra1406184. View